Expert Interview
A Third View: Taking a look at the ongoing NTLA's study of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy and BBIO's phase 3 attribute-cm study of acoramidis in patients with transthyretin (ATTR) amyloidosis
Ticker(s): NTLA, BBIO- Director, Heart & Vascular Center
- 20-24 patients with ATTR amyloidosis
- Aware of PRONTO study (investigational drug phase II), drug trial vutrisiran, isatuximab, epidemiology study with patrisiran, and a PET/MR study for diagnosis.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
